Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.